| Literature DB >> 18174945 |
Gunnar Toft1, Manhai Long, Tanja Krüger, Philip S Hjelmborg, Jens Peter Bonde, Anna Rignell-Hydbom, Ewa Tyrkiel, Lars Hagmar, Aleksander Giwercman, Marcello Spanó, Davide Bizzaro, Henning S Pedersen, Vladymir Lesovoy, Jan K Ludwicki, Eva C Bonefeld-Jørgensen.
Abstract
BACKGROUND: Semen quality in humans may be influenced by exposure to endocrine-disrupting compounds.Entities:
Keywords: CALUX; androgen receptor; aryl hydrocarbon receptor; endocrine disruption; estrogen receptor; human; sperm
Mesh:
Substances:
Year: 2007 PMID: 18174945 PMCID: PMC2174408 DOI: 10.1289/ehp.9352
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Characteristics of samples with measures of semen quality and at least one of the xenohormone assays.
| Characteristic | Warsaw, Poland ( | Greenland ( | Kharkiv, Ukraine ( | Fishermen, Sweden ( |
|---|---|---|---|---|
| Outcomes | ||||
| Sperm concentration × 106/mL [median (5th–95th)] | 59 (8–241) | 48 (11–152) | 56 (17–159) | 53 (9–192) |
| Total sperm count × 106/mL [median (5th–95th)] | 190 (19–1,310) | 160 (25–650) | 170 (35–750) | 160 (15–480) |
| Volume [mL; median (5th–95th)] | 3.8 (1.3–7.2) | 3.0 (1.2–7.2) | 3.1 (1.3–7.9) | 2.8 (0.8–7.2) |
| Percent of A + B motile [mean (5th–95th)] | 56 (0–85) | 50 (19–79) | 57 (19–88) | 57 (15–89) |
| Percent of normal morphology [median (5th–95th)] | 6 (2–12) | 6 (2–14) | 8 (1–16) | 7 (1–16) |
| Exposure markers | ||||
| XER activity RLU/mL serum [median (5th–95th)] | 3.1 (2.6–5.5) | 2.9 (2.3–3.4) | 3.2 (2.4–4.0) | 3.0 (2.6–4.1) |
| XER-EEQ [pg/g lipid; median (5th–95th)] | 130 (44–520) | — | 140 (80–580) | 84 (50–360) |
| XER competitive activity [RLU/mL serum; median (5th–95th)] | 3.0 (2.5–5.8) | 2.7 (2.2–3.3) | 2.9 (2.2–3.5) | 2.9 (2.0–3.5) |
| XAR activity [RLU/mL serum; median (5th–95th)] | 3.5 (2.2–6.4) | 3.9 (2.6–5.6) | 3.6 (2.3–5.0) | 3.7 (2.4–5.8) |
| XAR competitive activity [RLU/mL serum; median (5th–95th)] | 3.0 (1.9–4.1) | 4.0 (3.2–6.0) | 2.2 (1.3–3.3) | 2.9 (2.0–4.6) |
| AhR activity [RLU/mL serum; median (5th–95th)] | 36 (15–74) | 18 (8–62) | 27 (15–45) | 34 (12–75) |
| AhR-TEQ [pg/g lipid; median (5th–95th)] | 320 (130–360) | 190 (100–600) | 330 (180–630) | 460 (220–920) |
| AhR competitive activity [RLU/mL serum; median (5th–95th)] | 6.5 (4.6–8.3) | 7.8 (5.8–10.5) | 6.7 (1.8–9.8) | 6.1 (4.7–8.3) |
| Potential confounders | ||||
| Abstinence period days [median (5th–95th)] | 3.0 (1–30) | 2.5 (0.5–7.0) | 3.0 (2.0–7.0) | 3.0 (1.0–10.0) |
| Age [mean years (5th–95th)] | 30 (26–38) | 30 (20–40) | 28 (20–38) | 46 (32–62) |
| Time to analysis [min; mean (5th–95th)] | 51 (40–65) | 34 (30–50) | 36 (25–63) | 46 (25–65) |
| Body mass index [kg/m2; mean (5th–95th)] | 26 (20–32) | 26 (20–32) | 24 (20–30) | 26 (22–31) |
| Season for sperm collection (%) | ||||
| Spring | 5 | 46 | 0 | 53 |
| Summer | 24 | 0 | 3 | 28 |
| Fall | 30 | 54 | 57 | 19 |
| Winter | 41 | 0 | 40 | 0 |
| Fever last three months (%) | 11 | 11 | 8 | 4 |
| Urogenital infections (%) | 6 | 85 | 1 | 22 |
| Urogenital surgery (%) | 2 | 0 | 0 | 1 |
| Spillage yes (%) | 10 | 13 | 14 | 16 |
| Current smoking (%) | 30 | 81 | 71 | 23 |
| Alcohol consumption [> 21 drinks/week (%)] | 4 | 8 | 0 | NA |
NA, not applicable; 5th–95th, range of 5th–95th percentiles.
Frequency of samples with ER agonistic effect 21% (Warsaw), 1% (Greenland), 14% (Kharkiv), and 12% (Sweden), respectively.
Calculated on data from samples with agonistic effects only. Agonistic activity calculated as samples (triplicates) that differed significantly from the solvent control values using Student t-test. For details see Bonefeld-Jorgensen et al. (2006), Long et al. (2006). The equivalence factor for AR (XAR-TEQ) could not be calculated because the weak agonistic responses did not reach the linear range of the R1881 (positive control) dose–response curve.
One subject only, data not presented.
Frequency of samples with ER antagonistic effect 7% (Warsaw), 71% (Greenland), 30% (Kharkiv), and 19% (Sweden), respectively.
Frequency of samples with AR agonistic effect 25% (Warsaw), 35% (Greenland), 26% (Kharkiv), and 34% (Sweden), respectively.
Frequency of samples with AR antagonistic effect 21% (Warsaw), 3% (Greenland), 50% (Kharkiv), and 8% (Sweden), respectively.
Frequency of samples with AhR agonistic effect 100% (Warsaw), 92% (Greenland), 100% (Kharkiv), and 95% (Sweden), respectively.
Frequency of samples with AhR antagonistic effect 8% (Warsaw), 3% (Greenland), 34% (Kharkiv), and 12% (Sweden), respectively.
Coefficient of variation in the different xenobiotic assays.
| Intra-assay CV (between aliquots from the same sample) | Solvent control interassay CV | Solvent control + ligand (-comp) interassay CV | Interassay CV (pooled serum samples run in each assay) | |
|---|---|---|---|---|
| XER | 5 | 1 | 2 | 13 |
| XAR | 11 | 11 | 13 | 31 |
| AhR | 11 | 17 | 18 | — |
Not analyzed in this assay.
Analysis of homogeneity across populations and results of multiple linear regressions of semen characteristics on xenobiotic serum activity in the aggregated data set adjusted for study population.
| Log sperm concentration | Motile sperm | Normal sperm cells
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| β (95% CI) | Geometric mean sperm conc (95% CI) | β (95% CI) | Mean motility (95% CI) | β (95% CI) | Geometric mean normal sperm cell (95% CI) | ||||
| XER activity | 0.53 | 0.09 (−0.01 to 0.20) | 53 (48–58) | 0.86 | 1.60 (−1.31 to 4.52) | 56 (54–58) | 0.91 | 0.05 (−0.03 to 0.13) | 7.0 (6.5–7.5) |
| XER activity < 3.14 | 0.17 | 0.40 (0.01 to 0.79) | 55 (49–62) | 0.15 | 10.2 (0.2 to 20.2) | 56 (52–59) | 0.61 | −0.06 (−0.36 to 0.24) | 6.6 (6.0–7.2) |
| XER activity ≥ 3.14 | 0.24 | 0.14 (0.02 to 0.28) | 51 (43–59) | 0.70 | 1.6 (−2.1 to 5.3) | 54 (50–58) | 0.87 | 0.03 (−0.07 to 0.12) | 7.6 (6.8–8.5) |
| XER-EEQ (pg/g lipid) | 0.56 | < 0.001 (−0.002 to 0.002) | 57 (43–75) | 0.63 | 0.02 (−0.03 to 0.07) | 54 (47–61) | 0.60 | 0.0006 (−0.0009 to 0.0021) | 6.7 (5.5–8.1) |
| XER competitive activity | 0.98 | −0.08 (−0.22 to 0.05) | 54 (49–59) | 0.45 | −1.7 (−5.4 to 2.0) | 56 (54–59) | 0.25 | −0.009 (−0.11 to 0.09) | 7.0 (6.6–7.5) |
| XERcomp activity < 3.14 | 0.78 | −0.15 (−0.48 to 0.18) | 54 (49–60) | 0.93 | −6.4 (−15.3 to 2.5) | 55 (52–58) | 0.74 | −0.18 (−0.43 to 0.07) | 7.1 (6.6–7.7) |
| XERcomp activity ≥ 3.14 | 0.92 | −0.10 (−0.32 to 0.12) | 52 (44–63) | 0.53 | −4.6 (−10.1 to 0.8) | 58 (53–63) | 0.99 | 0.05 (−0.11 to 0.22) | 6.9 (6.0–7.9) |
| XAR activity | 0.10 | −0.06 (−0.14 to 0.02) | 58 (52–64) | 0.82 | −0.5 (−2.8 to 1.8) | 56 (54–59) | 0.76 | 0.01 (−0.05 to 0.07) | 7.1 (6.6–7.7) |
| XAR activity < 3.14 | 0.62 | 0.11 (−0.34 to 0.57) | 60 (50–73) | 0.15 | 9.4 (−5.2 to 23.9) | 59 (53–65) | 0.86 | 0.18 (−0.27 to 0.62) | 6.9 (6.0–8.1) |
| XAR activity ≥ 3.14 | 0.31 | −0.07 (−0.17 to 0.03) | 58 (52–65) | 0.45 | 0.2 (−2.7 to 3.1) | 55 (51–58) | 0.51 | 0.01 (−0.06 to 0.08) | 7.1 (6.5–7.8) |
| XAR competitive activity | 0.03 | — | 58 (52–64) | 0.96 | 0.7 (−3.4 to 4.7) | 56 (54–59) | 0.62 | 0.00 (−0.11 to 0.11) | 7.1 (6.6–7.7) |
| XARcomp activity < 3.14 | 0.39 | −0.12 (−0.40 to 0.16) | 64 (55–75) | 0.74 | −3.0 (−11.6 to 5.6) | 54 (50–59) | 0.03 | — | 6.9 (6.1–7.7) |
| XARcomp activity ≥ 3.14 | 0.92 | 0.04 (−0.21 to 0.28) | 53 (45–63) | 0.54 | 1.9 (−5.4 to 9.1) | 58 (52–62) | 0.67 | 0.04 (−0.16 to 0.25) | 7.3 (6.4–8.4) |
| AhR activity | 0.03 | — | 55 (50–61) | 0.85 | 0.07 (–0.07 to 0.20) | 56 (53–58) | 0.76 | 0.004 (−0.002 to 0.009) | 7.0 (6.6–7.5) |
| AhR-TEQ (pg/g lipid) | 0.001 | — | 55 (50–61) | 0.08 | −0.004 (−0.02 to 0.01) | 56 (53–59) | 0.19 | 0.0002 (−0.0002 to 0.0005) | 7.0 (6.5–7.5) |
| AhR competitive activity | 0.94 | −0.01 (−0.07 to 0.05) | 55 (50–61) | 0.77 | −0.2 (−1.7 to 1.3) | 56 (53–58) | 0.98 | 0.007 (−0.03 to 0.05) | 7.0 (6.6–7.5) |
| AHRcomp activity < 6.67 | 0.27 | −0.04 (−0.17 to 0.09) | 54 (47–63) | 0.88 | 0.7 (−8.4 to 9.7) | 58 (54–62) | 0.43 | −0.007 (−0.11 to 0.09) | 6.8 (6.2–7.6) |
| AHRcomp activity ≥ 6.67 | 0.26 | −0.05 (−0.17 to 0.06) | 55 (48–63) | 0.34 | 2.2 (−1.0 to 5.3) | 53 (50–57) | 0.95 | −0.03 (−0.30 to 0.23) | 7.2 (6.5–7.9) |
Abbreviations: —, combined analyses were not performed due to lack of homogeneity across populations; conc, concentration.
Adjusted for age and abstinence time.
Restricted to samples analyzed within 1 hr after collection.
RLU/mL serum; solvent controls were 3.13 RLU/mL serum (XER and XAR) and 6.67 RLU/mL serum (AhR).
Significant associations (p < 0.05).
Figure 1Sperm concentration (A) and sperm motility (B) in relation to XER activity in the four populations. Reference value = 3.14.